Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9931315 Method of selectively inhibiting Ras-mediated tumor growth in humans

Patent 9931315 was granted and assigned to ADT Pharmaceuticals, LLC on April, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

‌

ADT Pharmaceuticals, LLC

Current Assignee

‌

ADT Pharmaceuticals, LLC

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9931315

Patent Inventor Names

Gary A. Piazza0

Xi Chen0

Adam B. Keeton0

Michael R. Boyd0

Date of Patent

April 3, 2018

Patent Application Number

15056202

Date Filed

February 29, 2016

Patent Citations Received

‌

US Patent 11680073 Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses

‌

US Patent 11834404 Derivatives of sulindac can protect normal cells against oxidative damage

Patent Primary Examiner

‌

Timothy P Thomas

Patent abstract

Disclosed are compounds, for example, a compound of formula I,

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9931315 Method of selectively inhibiting Ras-mediated tumor growth in humans

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API